Common Stock, par value $0.001
- Symbol
- EYPT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
EyePoint, Inc.
EYPTNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On October 19, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing topline data for LUCIA, one of its pivotal Phase 3 clinical trials evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.…
Company context
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by FEDERATED HERMES, INC. regarding EyePoint, Inc.Nov 4, 2026
- SCHEDULE 13G - filed by TANG CAPITAL MANAGEMENT LLC regarding EyePoint, Inc.Oct 27, 2026
- Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Other EventsOct 19, 2026
- SCHEDULE 13G/A - filed by FEDERATED HERMES, INC. regarding EyePoint, Inc.Oct 7, 2026
- Other EventsSep 10, 2026
Registered securities in this filing
EyePoint, Inc. · 8-K · Filed 2026-10-19
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On October 19, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing topline data for LUCIA, one of its pivotal Phase 3 clinical trials evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Additionally, on October 19, 2026, the Company posted an updated investor presentation on its website at www.eyepoint.bio. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.
Filed exhibits (2)
Exhibit 99.1 EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYUTM in Wet AMD - LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement - - Key secondary endpoints in LUCIA were met including a superior 38% reduction in treatment burden (nominal p-value <0.0001), with 52% of eyes supplement-free and 71% receiving zero or one supplement up to Week 56, as well as strong anatomic control - - Continued favorable safety profile for DURAVYU with redosing - ─ DME program remains on track with pivotal Phase 3 topline data from two identical clinical trials anticipated in Q4 2027 - - Conference call to discuss the results to be held today at 8:00 a.m. EDT - WATERTOWN, Mass., October 19, 2026 (GLOBE NEWSWIRE) - EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced topline results from LUCIA, the second pivotal Phase 3 clinical trial of DURAVYUTM (vorolanib intravitreal insert) for the tre…
Open exhibit ↗LUCIA Phase 3 Clinical Trial DURAVYU in Wet AMD Topline Results | October 2026 Exhibit 99.2 Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, are forward-looking statements, including but not limited to statements regarding: our expectations regarding our clinical development and regulatory plans; our plans to conduct additional analyses to assess the potential of DURAVYU as a treatment for wet AMD; our belief regarding DURAVYU’s potential mechanistic edge as only TKI combining VEGF receptor blockade, IL-6/JAK1 anti-inflammatory and PDGF antifibrotic benefit; our belief that our Phase 3 DME COMO and CAPRI trial designs position DURAVYU for clinical and global regulatory and commercial success; our expectations regarding the timing of the availability of DME clinical data, including topline results for clinical trials in DME in the fourth quarter of 2027…
Open exhibit ↗